Jagran Josh Logo

Glenmark Pharma received final approval of USFDA for migraine drug

Mar 16, 2016 13:17 IST

Glenmark Pharmaceuticals on 14 March 2016 announced that it received the final approval from the US Food and Drug Administration (USFDA) to manufacture and market Frovatriptan Succinate tablets in the American market.

The Frovatriptan Succinate Tablets, 2.5 mg, which is therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg, has an estimated market size of 87.8 million US dollars for the 12 months ended January 2016.

Used of Frovatriptan Succinate

Frovatriptan is used to treat migraines and helps to relieve other migraine symptoms.

It belongs to a class of drugs known as triptans.

It affects a certain natural substance (serotonin) that causes narrowing of blood vessels in the brain.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.

It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.

The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.

Now get latest Current Affairs on mobile, Download # 1  Current Affairs App

Is this article important for exams ? Yes2 People Agreed
Read more Current Affairs on: Glenmark , Glenmark Pharma , Endo Pharmaceutical , Frova , Migraines

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

Newsletter Signup
Follow us on
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK